Evidence map›Paper›PMID 29544502›Full record

ArticleJournal of neuroinflammation2018

Cell-type- and region-specific restriction of neurotropic flavivirus infection by viperin.

Richard Lindqvist, Chaitanya Kurhade, Jonathan D Gilthorpe, Anna K Överby

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Getting on your last nerve: IFNs and resistance to infection.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Review
  3. Article
  4. Article
  5. Langat Virus Biology and Infection.Reviews in medical virology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Zika Virus Neuropathogenesis-Research and Understanding.Pathogens (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Mechanisms of Zika astrocyte infection and neuronal toxicity.NeuroImmune pharmacology and therapeutics · 2023
    Article
  16. Immune Functions of Astrocytes in Viral Neuroinfections.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Review
  19. Shiftless inhibits flavivirus replication in vitro and is neuroprotective in a mouse model of Zika virus pathogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  20. Viperin is anti-viralThe Journal of general virology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Richard LindqvistDepartment of Clinical Microbiology, Virology, Umeå University, 90185, Umeå, Sweden.
Chaitanya KurhadeDepartment of Clinical Microbiology, Virology, Umeå University, 90185, Umeå, Sweden.
Jonathan D GilthorpeDepartment of Pharmacology and Clinical Neurosciences, Umeå University, 90187, Umeå, Sweden.
Anna K ÖverbyDepartment of Clinical Microbiology, Virology, Umeå University, 90185, Umeå, Sweden. anna.overby@umu.se.
Umeå University · SE

Funding

Stiftelsen för Strategisk Forskning FFL12-0089Stiftelsen för Strategisk Forskning ICA10-0059Vetenskapsrådet 2011-2795Vetenskapsrådet 2017-02438
6 · The paper itself

Abstract

backgroundFlaviviruses are a group of diverse and emerging arboviruses and an immense global health problem. A number of flaviviruses are neurotropic, causing severe encephalitis and even death. Type I interferons (IFNs) are the first line of defense of the innate immune system against flavivirus infection. IFNs elicit the concerted action of numerous interferon-stimulated genes (ISGs) to restrict both virus infection and replication. Viperin (virus-inhibitory protein, endoplasmic reticulum-associated, IFN-inducible) is an ISG with broad-spectrum antiviral activity against multiple flaviviruses in vitro. Its activity in vivo restricts neurotropic infections to specific regions of the central nervous system (CNS). However, the cell types in which viperin activity is required are unknown. Here we have examined both the regional and cell-type specificity of viperin in the defense against infection by several model neurotropic flaviviruses.

methodsViral burden and IFN induction were analyzed in vivo in wild-type and viperin

resultsViperin activity restricted nonlethal LGTV infection in the spleen and the olfactory bulb following infection via a peripheral route. Viperin activity was also necessary to restrict LGTV replication in the olfactory bulb and the cerebrum following CNS infection, but not in the cerebellum. In vitro, viperin could restrict TBEV replication in primary cortical neurons, but not in the cerebellar granule cell neurons. Interferon-induced viperin was also very important in primary cortical neurons to control TBEV, WNV, and ZIKV.

conclusionsOur findings show that viperin restricts replication of neurotropic flaviviruses in the CNS in a region- and cell-type-specific manner. The most important sites of activity are the olfactory bulb and cerebrum. Activity within the cerebrum is required in the cortical neurons in order to restrict spread. This study exemplifies cell type and regional diversity of the IFN response within the CNS and shows the importance of a potent broad-spectrum antiviral ISG.

Indexed as

AnimalsAntiviral AgentsAstrocytesCells, CulturedCerebrumDisease Models, AnimalFlavivirusFlavivirus InfectionsGene Expression Regulation, ViralInterferon-alphaMiceMice, Inbred C57BLMice, TransgenicNeuronsOlfactory BulbProteinsAntiviral AgentsInterferon-alphaProteinsRsad2 protein, mouseViperin ProteinAstrocytesFlavivirusInterferonNeuronsViperin

Identifiers

PMID29544502
PMCPMC5856362
OpenAlexW2793701587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.